265989-50-2

265989-50-2 structure

Name: Ortho-hydroxy atorvastatin lactone-d5
Chemical Name: 5-(4-fluorophenyl)-1-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-N-(2-hydroxyphenyl)-4-(2,3,4,5,6-pentadeuteriophenyl)-2-propan-2-ylpyrrole-3-carboxamide
CAS Number: 265989-50-2
Molecular Formula: C₃₃H₂₈D₅FN₂O₅
Molecular Weight: 561.65
Catalog: Research Areas Cardiovascular Disease
Create Date: 2018-06-11 17:11:49
Modify Date: 2024-01-08 18:03:45
Ortho-hydroxy atorvastatin lactone-d5 is deuterium labeled 2-Hydroxy atorvastatin lactone. 2-Hydroxy atorvastatin lactone is a metabolite of Atorvastatin. Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids[1][2].

Name	5-(4-fluorophenyl)-1-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-N-(2-hydroxyphenyl)-4-(2,3,4,5,6-pentadeuteriophenyl)-2-propan-2-ylpyrrole-3-carboxamide
Synonyms	2-Hydroxy Atorvastatin Lactone-d5

Description	Ortho-hydroxy atorvastatin lactone-d5 is deuterium labeled 2-Hydroxy atorvastatin lactone. 2-Hydroxy atorvastatin lactone is a metabolite of Atorvastatin. Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids[1][2].
Related Catalog	Research Areas >> Cardiovascular Disease
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Guo CX, et al. Effects of Ginkgo biloba extracts on pharmacokinetics and efficacy of atorvastatin based on plasma indices. Xenobiotica. 2012;42(8):784‐790. [3]. Turner NA, et al. Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion. J Cardiovasc Pharmacol. 2007 Oct;50(4):458-61.